Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study

Youn H. Kim, M. Bagot, Pier Luigi Zinzani, Madeleine Duvic, Stephen Morris, Ellen Kim, Amy Musiek, Pablo L. Ortiz‐Romero, Craig A. Elmets, Herbert Eradat, Nina Magnolo, Julia Scarisbrick, Stéphane Dalle, David C. Fisher, Michi M. Shinohara, Brian Poligone, Barbara Pro, Pietro Quaglino, Nishitha Reddy, Brigitte Dréno, Larisa J. Geskin, Ahmad Halwani, Amit Khot, M. Beylot‐Barry, Neil J. Korman, Frederick Lansigan, Sarah McCue Horwitz, Zanetta S. Lamar, Alison J. Moskowitz, Jillian Wells, Oleg E. Akilov, Dolores Caballero, Richard Cowan, Reinhard Dummer, Mary Jo Lechowicz, Francine M. Foss, Lars Iversen, Tomomitsu Miyagaki, Ryan Wilcox, Pierluigi Porcu, Maarten H. Vermeer, Sunil Abhyankar, Yukihiko Kato, Theresa R. Pacheco, Shigetoshi Sano, Basem M. William, Timothy S. Fenske, Noriko Fukuhara, Koji Habe, Toshihisa Hamada, Eiji Kiyohara, Bryone J. Kuss, Adam Lerner, Lawrence A. Mark, Javier Muñoz, Hiroyuki Okamoto, Christiane Querfeld, Jiro Uehara, Hisashi Uhara, Kentaro Yonekura, Auris Huen, Kensei Tobinai, Y. Tokura, Erin Boh, Jan P. Nicolay, Hidefumi Wada, Mollie Leoni, Takahiro Ito, Fiona Herr, Lubomir Sokol (2019). Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study. , 134(Supplement_1), DOI: https://doi.org/10.1182/blood-2019-122778.